More recently, the PD‐L1 antibody, durvalumab, was also approved by the FDA in combination with etoposide plus platinum chemotherapy as a first‐line treatment for adult patients with ES‐SCLC, based on the results of the Phase III CASPIAN trial.14 This evidence concerns the gene CD274 and small cell lung carcinoma.